Clinicopathologic and Survival Characteristics of Childhood and Adolescent Non Hodgkin's Lymphoma in Yazd, Iran

Binesh, Fariba; Akhavan, Ali; Behniafard, Nasim; Atefi, Aref

doi:10.7314/apjcp.2014.15.4.1585

Cited by 8 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their overall survival rate was worse than EBV-DLBCLs (Park et al, 2007;Dojcinov et al, 2011;Ok et al, 2015). Few studies about lymphomas have been done previously in Yazd, center of Iran in a limited number of cases (Binesh et al, 2013). Only few studies have focused on the EBV status in DLBCL of young adults (Cohen et al, 2014;Hong et al, 2015;Ok et al, 2015;Uccini et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: is it different between Over and Under 50 Years of Age?

Monabati

Vahedi²,

Safaei³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL) of the elderly is an entity introduced in the latest WHO classification of lymphoid tumors and defined in patients older than 50 years without prior lymphoma or immunodeficiency. However, recently it has also been seen in patients under 50. There is thus debate as to whether these are separate entities. Materials and Methods: In this retrospective study, we analyzed de novo DLBCL admitted to our institute over a period of two years. Clinical data included age, sex, nodal and extranodal presentation. The results of an immunohistochemistry (IHC) panel were also reviewed. IHC findings were mainly used to sub-classify DLBCL as germinal center vs. non germinal center types. IHC for identification of LMP-1 (latent membrane protein) and in situ hybridization for detection of EBVencoded RNA (EBER) was performed. EBV prevalence, clinical data and IHC findings were compared between patients under and over 50 years of age. Results: Out of 95 DLBCL, 11.6% were EBV positive (7.5% and 14.5% in the young and old groups). We did not find any significant differences in IHC subclasses and clinical data between EBV positive DLBCL (EBV+DLBCL) of young and old groups. Conclusions: EBV+DLBCL are not exclusive to patients older than 50 years. With regard to clinical data as well as IHC subclasses, no differences were evident between EBV+DLBCL of young and old groups. Our suggestion is to eliminate any cut off age for EBV+DLBCL.

show abstract

Section: Introductionmentioning

confidence: 99%

Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: is it different between Over and Under 50 Years of Age?

Monabati

Vahedi²,

Safaei³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The optimal first-line therapy for ENKL is evolving. The 5-year survival rates of limited stage ENKL treated with radiotherapy alone or with combination chemotherapy are both below 50% (Li et al, 2006;Zhang et al, 2013;Binesh et al, 2014). The main treatment for late stage ENKL is chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Tolerance of Pegaspargase-Based Chemotherapy in Patients with Nasal-Type Extranodal NK/T-Cell Lymphoma: a Pilot Study

Wen

Li²,

Li³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Actually in spite of common genetic abnormality, patients with MCL show variant c y t o m o r p h o l o g y a n d t u m o r a r c h i t e c t u r e a n d immunophenotype which may impact prognosis and even treatment protocol. Although few studies were done on subtype distribution of lymphoma in Iran [8][9][10] in our knowledge, there is no specific study on clinicopathologic findings of MCL here. MCL comprises approximately 4% of malignant lymphoma in the province of British Columbia [2] accounts for 6% of all NHLs in the USA [11] and 3.2% of all malignant lymphoma in turkey [12].…”

Section: Discussionmentioning

confidence: 89%

Mantle cell lymphoma: pathologic and immunophenotyping study of 50 cases and correlation with survival—a single institute experience

et al. 2020

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is a relatively rare lymphoma subtype. Almost all cases show common genetic abnormality t(11;14), resulting in overexpression of cyclin D1 protein. The clinical course is usually aggressive, and the disease is mainly considered incurable but obvious clinical heterogeneity exists. Most patients experience a rapidly progressive course, and some go through an indolent course of disease. So new strategies are needed for risk stratification and may allow for a more personalized approach in the future. We retrospectively studied 50 cases of MCL which were diagnosed at a single center over about 5 years to determine clinicopathologic and immunophenotyping findings. This study focuses on (1) age, gender, and location of tumor at presentation; (2) some challenges in the diagnostic criteria; (3) cytomorphology, histomorphology, immunophenotyping, and proliferation rate; and (4) overall survival and finally relationship with demographic and pathologic findings which shows no association between survival of patients and gender, cytomorphology, histology, and location of tumor while increased mitotic activity and age are prognostically important factors. Cyclin D1 immunostaining is strictly recommended in all low-grade B cell lymphoma due to absence of CD5 expression on 20% of confirmed MCL and also on all high-grade B cell lymphoma for avoiding overlook of blastic variant of MCL.

show abstract

Clinicopathologic and Survival Characteristics of Childhood and Adolescent Non Hodgkin's Lymphoma in Yazd, Iran

Cited by 8 publications

References 17 publications

Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: is it different between Over and Under 50 Years of Age?

Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: is it different between Over and Under 50 Years of Age?

Efficacy and Tolerance of Pegaspargase-Based Chemotherapy in Patients with Nasal-Type Extranodal NK/T-Cell Lymphoma: a Pilot Study

Mantle cell lymphoma: pathologic and immunophenotyping study of 50 cases and correlation with survival—a single institute experience

Contact Info

Product

Resources

About